Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.
Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
Overcoming Barriers to MASLD/MASH Screening in Clinical Practice
In this episode of Expose MASH [formerly NASH], our experts will discuss some of the major barriers to screening for MASLD/MASH in the primary care and endocrinology settings. They will identify these barriers and misconceptions that contribute to the low rates of MASLD/MASH diagnosis, and provide their perspectives on how we can best overcome these challenges. This episode is brought to you by Novo Nordisk Inc.
17 Nov 2025
Advanced Practice Providers: A Pillar of Patient Care in MASH
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only— we discuss the role that advanced practice providers (APPs) play in the screening and identification of patients with MASH (metabolic dysfunction-associated steatohepatitis). We explore their influence on patient care, their role in coordinating care, and discuss how their involvement in the MASH patient journey can impact patient outcomes. This episode is brought to you by Novo Nordisk Inc.
4 Nov 2025
Cardiovascular Disease and the Liver: A Unified Approach for MASH
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we break down the connection between liver and heart disease, focusing on how MASH (metabolic dysfunction-associated steatohepatitis) can increase the risk of cardiovascular disease, and how addressing MASH can help by treating risk factors common to heart disease and MASLD can benefit both heart and liver. We explore why patients with MASH face higher mortality rates, often due to cardiovascular complications, and discuss the importance of integrated care between hepatologists and cardiologists. This episode is brought to you by Novo Nordisk Inc.
Liver specialists, Dr. [Last Name] and Dr. [Last Name], highlight the urgency of MASH screening to prevent fibrosis progression and reduce associated morbidity and mortality.
17 Oct 2024
A Practical Translation Guide: Turning MASH Guidelines Into Practice
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we will share insights on the current MASH guidelines. The adoption of the new MASH nomenclature, with the inclusion of cardiometabolic risk factors into its formal definition, will be briefly discussed before examining the different clinical guidelines that are available. We will identify shared recommendations and key points of difference for the screening and management of this complex disease. We will then look to the future to discuss how emerging data may inform future guidelines and help optimize clinical practice. This episode is brought to you by Novo Nordisk Inc.
2 Oct 2024
Exploring FIB-4 for Fibrosis Risk Assessment
In this sixth episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we share insight on primary fibrosis risk assessment using the FIB-4 index in patients with MASH (metabolic dysfunction-associated steatohepatitis). Our experts explain the importance of noninvasive tests as a useful tool to identify patients at high risk for MASH. Futhermore, they discuss the relevance of using the FIB-4 test in order to facilitate timely intervention for these at-risk patients. This episode is brought to you by Novo Nordisk Inc.
19 Sept 2024
Empowering Patients: Strategies for Education on Liver Health
Join us on this episode of Expose MASH—intended for US healthcare professionals only—as our experts share their approaches to educating patients about MASH and overall liver health. The conversation will examine the importance of educating patients on the disease and how effectively communicating with patients can help raise awareness of MASH, increase screening, and improve diagnosis rates and management of this condition. Our experts will discuss best practices for educating patients on key aspects of MASLD and MASH, including understanding the disease, its prevalence, and progression. Furthermore, the conversation will explore the importance of patient and HCP conversations to improve early risk identification and impact overall liver health. This episode is brought to you by Novo Nordisk Inc.
5 Sept 2024
Connecting Metabolic Dots in the Context of MASH
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we take a closer look at the pathophysiology of MASH (metabolic dysfunction-associated steatohepatitis) to understand which patients are at high risk for MASH. Join us as we discuss the systemic dysfunction at the root of MASH and other metabolic disorders, exploring how shared disease pathways can help inform patient identification, screening, and holistic patient management. This episode is brought to you by Novo Nordisk Inc.
9 Aug 2024
The MASH Journey: Today, Tomorrow, and Beyond
Join us in the third episode of Expose MASH [formerly NASH], as our experts turn their attention to the heart of the matter: the patients. We will explore the MASH patient journey, from initial symptoms to living with MASH. Our conversation will focus on the urgency for improved identification of at risk patients, guidelines for testing, and effective disease management. Our experts will discuss risk assessment and how to manage patient’s comorbidities. Furthermore, we will explore the importance of coordinated care between HCPs and liver specialists to provide a holistic approach to MASH management.
24 Jul 2024
MASH Crossroads: The Liver and Patients at Risk
This second episode of Expose MASH [formerly NASH] will deep dive into how metabolic syndrome can contribute to liver disease. Our experts will explore why MASH is a cardiometabolic disorder and how this new perspective on liver disease can lead to improvements in identifying at-risk patients and managing cardiometabolic comorbidities. Join us as we navigate through this episode, offering a deeper understanding of the intersection between cardiometabolic dysfunction and liver health.
8 Jul 2024
MASH is the New NASH
In this first episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we embark on a journey into the world of MASH (metabolic dysfunction-associated steatohepatitis). Our experts will explain what MASH is and share their insights on the new MASH name, offering a glimpse into how it may help to reshape the landscape of liver disease screening, diagnosis, and management. Join us as we explore the MASH disease state and lay the foundation for future episodes focused on specific aspects of MASH screening and management.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.3 / 5
13 ratings
Contact Expose MASH [Formerly NASH]
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Expose MASH [Formerly NASH]?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
![Expose MASH [Formerly NASH]](https://pod-engine-public.nyc3.cdn.digitaloceanspaces.com/images/FscXw7pPYb9pIkXbgryvMLmw35MxAZNv65pFlY0Rbg5.png)